Drug Trial Radar · NCT01067521
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
Last checked: Nov 20, 2026Latest source record: Dec 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,404
Actual
Start
Jun 22, 2010
Primary completion
May 8, 2012
Study completion May 12, 2017
Sponsor
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.Teva (TEVA)
- Sponsor type
- Industry
- First posted
- Feb 11, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is designed to assess the efficacy of Glatiramer Acetate (GA) injection 40 mg administered three times a week compared to placebo in subjects with RRMS, as measured by the number of confirmed relapses during the 12 month placebo controlled period. The study has two periods: * Placebo Controlled Period: 12 months of 40 mg administered three times a week by subcutaneous injection or matching placebo. * Open Label Extension Period: All subjects will continue treatment with GA 40 mg administered three times a week, until this dose strength is commercially available for the treatment of relapsing remitting multiple sclerosis (RRMS) patients or until the development of this GA dose regimen is stopped by the Sponsor
Conditions
- Relapsing Remitting Multiple Sclerosis
Interventions
Glatiramer acetate (GA)Drug
GA 40 mg/mL administered 3 times a week by subcutaneous injection for a period of 12 months for participants assigned to GA treatment in the Double-Blind Period, and GA 40 mg/mL administered 3 times a week by subcutaneous injection for all participants in the Open-Label Extension Period.
PlaceboDrug
Placebo comparator administered by subcutaneous injection three times each week for 12 months during the Double-Blind Period.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Total Number of Confirmed Relapses During the Placebo Controlled (PC) Treatment Period Estimated by Negative Binomial RegressionTime frame: Day 1 to 12 months
- Annualized Rate of Confirmed Relapses Comparing Early Starters to Delayed Starters Estimated by Negative Binomial RegressionTime frame: Day 1 up to 6.5 years
Locations
176 sites in 17 countries. Site status is shown where the registry gives one.
Teva Investigational Site 1332
Birmingham, Alabama
Teva Investigational Site 1327
Gilbert, Arizona
Teva Investigational Site 1311
Phoenix, Arizona
Teva Investigational Site 1326
Fullerton, California
Teva Investigational Site 1335
La Jolla, California
Teva Investigational Site 1297
Aurora, Colorado
Teva Investigational Site 1344
Boulder, Colorado
Teva Investigational Site 1315
Centennial, Colorado
Teva Investigational Site 1350
Fort Collins, Colorado
Teva Investigational Site 1345
Miami, Florida
Teva Investigational Site 1336
Naples, Florida
Teva Investigational Site 1347
Pompano Beach, Florida
Teva Investigational Site 1319
Ponte Vedra, Florida
Teva Investigational Site 1298
Sarasota, Florida
Teva Investigational Site 1316
Sarasota, Florida
Teva Investigational Site 1340
Tampa, Florida
Teva Investigational Site 1317
Vero Beach, Florida
Teva Investigational Site 1303
Northbrook, Illinois
Teva Investigational Site 1334
Lenexa, Kansas
Teva Investigational Site 1302
Lexington, Kentucky
Teva Investigational Site 1322
Shreveport, Louisiana
Teva Investigational Site 1306
Detroit, Michigan
Teva Investigational Site 1329
Akron, Ohio
Teva Investigational Site 1349
Columbus, Ohio
Teva Investigational Site 1313
Dayton, Ohio
Teva Investigational Site 1318
Uniontown, Ohio
Teva Investigational Site 1341
Oklahoma City, Oklahoma
Teva Investigational Site 1310
Nashville, Tennessee
Teva Investigational Site 1321
Lubbock, Texas
Teva Investigational Site 1337
Round Rock, Texas
Teva Investigational Site 1301
San Antonio, Texas
Teva Investigational Site 1346
San Antonio, Texas
Teva Investigational Site 1343
Salt Lake City, Utah
Teva Investigational Site 1338
Richmond, Virginia
Teva Investigational Site 1339
Roanoke, Virginia
Teva Investigational Site 1300
Vienna, Virginia
Teva Investigational Site 1323
Kirkland, Washington
Teva Investigational Site 5940
Blagoevgrad, Bulgaria
Teva Investigational Site 5931
Pleven, Bulgaria
Teva Investigational Site 5932
Pleven, Bulgaria
Showing 40 of 176 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.